Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

GB-5001 demonstrates safety in toxicity study in dogs

Aug. 5, 2021

Lumosa reports phase IIa data on LT-3001 in patients after acute ischemic stroke

Aug. 4, 2021

ALZ-201 neutralizes the neurotoxicity of postmortem brain extracts from patients with AD

Aug. 4, 2021

Disarm Therapeutics discovers NAD(+) hydrolase SARM1 inhibitors

Aug. 4, 2021

Antibe places its AME study of otenaproxesul on required pause

Aug. 4, 2021

Luye Pharma files IND in U.S. to study next-generation VMAT2 inhibitor LY-03015

Aug. 3, 2021

ACD-856 shows preclinical effects on cognition, enters phase I study

Aug. 3, 2021

Annovis reports interim phase II data on Posiphen in Alzheimer's and Parkinson's disease

Aug. 3, 2021

Gem gene sparkles as ischemic stroke drug discovery target

Aug. 3, 2021

Discovery of SR-42667: a tau-SH3 interaction inhibitor that prevents Abeta toxicity

Aug. 3, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...